Back to company

Resistance Oncology ApS: Financial statements 2021

CVR: 36945125

Resistance Oncology ApS (CVR 36945125) has filed annual accounts for 2021. In 2021, the company reported a gross profit of DKK -10,140 and a net result of DKK -8,615 compared with DKK -7,652 the year before. Equity amounted to DKK -31,179.

Gross Profit
-10,140 kr.
Profit/Loss
-8,615 kr.
Equity
-31,179 kr.
Total Assets
6,104 kr.

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2021--10 t.-9 t.-31 t.-
2020--10 t.-8 t.-23 t.-
2019-14 t.10 t.-15 t.-
2018--15 t.-13 t.-25 t.-
2017-51 t.1.1 mio.-12 t.0

Official annual report

View the official annual report directly on the page with a Pro subscription.

Find more companies like Resistance Oncology ApS

Build lead lists with filters on industry, geography, size and financials — and export straight to Excel.

Try the lead list generator

Events in 2021

Resistance Oncology ApS: The 2020 annual report is outJun 28, 2021

Resistance Oncology ApS has published its annual report for 2020. Gross profit came to DKK -9,500, and the net result was DKK -7,652.

About Resistance Oncology ApS

Resistance Oncology ApS is a Danish company of the type Anpartsselskab based in København K, founded in 2015. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named 3B-Oncology ApS and Cortris Nordic ApS. The management consists of Nils Aage Brünner and Kasper Pasternak Jørgensen. The company is owned by TIMPCO NB ApS, Alexander Meier Holding ApS and Pasternak Holding ApS. The company has 0 employees. In 2025, the company reported a gross profit of DKK -410,610 and a net result of DKK -665,070 compared with DKK -29,048 the year before. Equity amounted to DKK 325,631.